RxDoctor Payments DataLook up a doctor →

Adam Sills, MD

Dermatology · Jonesboro, ARNPI 1952326951

Payments from drug & device makers

$8,527in general payments, 2019–2025

Across 467 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Sun Pharmaceutical Industries Inc.$773
  • Johnson & Johnson$733
  • Novartis$647
  • UCB, Inc.$508
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$7,78191%
  • Education$7469%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,527 in reported general payments places this provider in the 75th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,615,203
Medicare patients
1,475
Services billed
12,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab26$348,330
Taltz AutoinjectorIxekizumab43$296,604
Skyrizi PenRisankizumab-Rzaa12$244,316
RinvoqUpadacitinib15$89,928
Cimzia (2 Pack)Certolizumab Pegol14$78,783
Dupixent SyringeDupilumab12$46,665
XolairOmalizumab11$30,469
Mycophenolate Mofetil37$4,430
Tacrolimus16$3,711
Ivermectin12$3,535
Clobetasol Propionate79$2,750
Triamcinolone Acetonide111$2,063
Doxycycline Hyclate103$1,740
Fluorouracil25$1,525
Ketoconazole68$1,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,730$89,92815 claims
UCB, Inc.Cimzia (2 Pack)$508$78,78314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 75 dermatology providers in Arkansas.

Other dermatology in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →